Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions

Psychopharmacology

Volumn 145, Issue 1, 1999, Pages 113-122

  Von Moltke, Lisa L ^a,b   Greenblatt, David J ^a,b   Granda, Brian W ^a,b   Grassi, Jeffrey M ^a,b   Schmider, Jürgen ^a,b   Harmatz, Jerold S ^a,b   Shader, Richard I ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450 3A; In vitro metabolism Drug interaction; Meta chlorophenylpiperazine; Nefazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; (4 HYDROXY 3 CHLOROPHENYL)PIPERAZINE; 3 HYDROXYNEFAZODONE; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BMS 183562; BMS 183695; BMS 33604; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; FLUVOXAMINE; HYDROXYNEFAZODONE; KETOCONAZOLE; NEFAZODONE; NORFLUOXETINE; POLYCLONAL ANTIBODY; QUINIDINE; TRAZODONE; TRIAZOLEDIONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; PRIORITY JOURNAL;

ALPRAZOLAM; ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PIPERAZINES; TRIAZOLES;

EID: 0032788134     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051039     Document Type: Article

References (41)

1. Adamus A, Sansone M, Melzacka M, Vetulani J (1985) Prolongation of thiopentone-induced sleep by trazodone and its metabolite, m-chlorophenylpiperazine. J Pharm Pharmacol 37:504-506
2. Barbhaiya RH, Shukla UA, Greene DS (1995a) Lack of interaction between nefazodone and cimetidine: A steady state pharmacokinetic study in humans. Br J Clin Pharmacol 40:161-165
3. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS (1995b) Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15:320-326
4. Barbhaiya RH, Shukla UA, Natarajan CS, Behr DA, Greene DS, Sainati SM (1995c) Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clin Pharmacol Ther 58:390-398
5. Barbhaiya RH, Buch AB, Greene DS (1996a) A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 16:915-923
6. Barbhaiya RH, Buch AB, Greene DS (1996b) Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 42:573-581
7. 14C] nefazodone in humans. Drug Metab Dispos 24:91-95
8. Barbhaiya RH, Shukla UA, Greene DS, Breuel H-P, Midha KL (1996d) Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 16:26-34
9. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235
10. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD (1990) Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311-315
11. Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J (1994) Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 8:463-473
12. Greenblatt DJ, von Moltke LL (1997) Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori W (ed) Drug-Drug Interactions: Analyzing In vitro-In vivo Correlations. International Business Communications, Southboro, Mass., pp 2.2.1-2.2.28
13. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI (1996) Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies. J Clin Pharmacol 36:792-798
14. Greene DS, Barbhaiya RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 4:260-275
15. Greene DS, Salazar DE, Pittman K, Barbhaiya RH (1995) Coadministration of nefazodone and benzodiazepines: III A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15:399-408
16. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM (1990) Effects of m-chlorophenylpiperazine in normal subjects: A dose-response study. Psychopharmacology 100:339-344
17. Kaul S, Shukla UA, Barbhaiya RH (1995) Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 35:830-839
18. Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, Meltzer HY (1997) Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 17:358-364
19. Marathe PH, Salazar DE, Greene DS, Brennan J, Shukla UA, Barbhaiya RH (1995) Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Pharm Res 12:1716-1721
20. Marathe PH, Lee JS, Greene DS, Barbhaiya RH (1996) Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Br J Clin Pharmacol 41:21-27
21. Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD (1997) The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. J Clin Psychopharmacol 17:27-33
22. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304-311
23. Rickels K, Schweizer D, Case WG, DeMartinis N, Greenblatt DJ, Mandos LA, España FG (1998) Nefazodone in major depression: Adjunctive benzodiazepine therapy and tolerablility. J Clin Psychopharmacol 18:145-153
24. Rotzinger S, Fang J, Coutts RT, Baker GB (1998) Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 44:1185-1191
25. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1995) N-Demethylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms, and effect of metabolic inhibitors. J Pharmacol Exp Ther 275:592-597
26. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI (1996a) Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation. Br J Clin Pharmacol 41:593-604
27. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI (1996b) Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450- directed antibodies. Pharmacology 52:125-134
28. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1996c) Inhibition of cytochrome P450 by nefazodone in vitro: Studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339-343
29. Shukla UA, Kaul S, Marathe PH, Pittman KA, Barbhaiya RH (1992) Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog. Eur J Drug Metabol Pharmacokinet 17:309-318
30. 14C] nefazodone in the dog. Drug Metabol Dispos 21:502-507
31. van Laar MW, van Willigenburg APP, Volkerts ER(1995) Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 15:30-40
32. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI (1998) Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 18:256
33. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI (1993) Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276
34. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI (1994a) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283
35. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994b) Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31
36. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131
37. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996a) Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128:398-407
38. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996b) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379
39. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI (1996c) Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791
40. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998a) Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 38:106-111
41. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI (1998b) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122